Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 95
- Registration Number
- NCT00428142
- Locations
- 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Humber River Regional Hospital, Toronto, Ontario, Canada
Rituxan in Churg Strauss Syndrome With Renal Involvement
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Fernando Fervenza
- Target Recruit Count
- 4
- Registration Number
- NCT00424749
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
- Conditions
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT00423098
- Locations
- 🇬🇧
Novartis, Cambridge, United Kingdom
🇫🇷Novartis Investigative Site, Paris, France
Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 313
- Registration Number
- NCT00419926
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 755
- Registration Number
- NCT00417079
- Locations
- 🇭🇺
Sanofi-Aventis Hungaria, Budapest, Hungary
🇫🇮sanofi-aventis Finland, Helsinki, Finland
🇮🇳sanofi-aventis India, Mumbai, India
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Christine Mauz-Körholz
- Target Recruit Count
- 648
- Registration Number
- NCT00416832
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT00416533
A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Ottawa Hospital Research Institute
- Registration Number
- NCT00414414
- Locations
- 🇿🇦
Erendale Hospital, Pietermaritzburg, KwaZulu Natal, South Africa
🇨🇦The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 222
- Registration Number
- NCT00413920
- Locations
- 🇫🇷
C.H.U. La Milétrie, Poitiers, France
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT00411528
- Locations
- 🇺🇸
University of Colorado Dept. of Univ. of Colorado, Aurora, Colorado, United States
🇺🇸University of California San Diego Dept of Moores Cancer Center, La Jolla, California, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.